Madrigal Pharmaceuticals, Inc.
MDGL
$425.85
-$9.77-2.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 432.05% | 864.21% | 3,421.98% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 432.05% | 864.21% | 3,421.98% | -- | -- |
| Cost of Revenue | 800.82% | 1,160.58% | 2,914.94% | -- | -- |
| Gross Profit | 418.84% | 853.05% | 3,445.01% | -- | -- |
| SG&A Expenses | 87.06% | 110.09% | 135.65% | 202.22% | 302.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.62% | 67.74% | 51.46% | 63.48% | 78.19% |
| Operating Income | 39.72% | 43.90% | 41.58% | 6.40% | -30.85% |
| Income Before Tax | 38.12% | 44.26% | 44.77% | 11.86% | -24.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.12% | 44.26% | 44.77% | 11.86% | -24.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.12% | 44.26% | 44.77% | 11.86% | -24.69% |
| EBIT | 39.72% | 43.90% | 41.58% | 6.40% | -30.85% |
| EBITDA | 39.89% | 44.08% | 41.77% | 6.57% | -30.74% |
| EPS Basic | 41.81% | 48.12% | 49.62% | 21.83% | -10.89% |
| Normalized Basic EPS | 42.36% | 48.61% | 49.62% | 21.83% | -10.89% |
| EPS Diluted | 41.81% | 48.12% | 49.62% | 21.83% | -10.89% |
| Normalized Diluted EPS | 42.36% | 48.61% | 49.62% | 21.83% | -10.89% |
| Average Basic Shares Outstanding | 5.32% | 6.99% | 10.46% | 13.87% | 13.84% |
| Average Diluted Shares Outstanding | 5.32% | 6.99% | 10.46% | 13.87% | 13.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |